Trial Radar AI | ||
|---|---|---|
De klinische studie NCT05976828 voor HPV-gerelateerde carcinoom is actief, niet rekruterend. Bekijk de kaartweergave van de Klinische Studies Radar en de AI-ontdekkingstools voor alle details. Of stel hier een vraag. | ||
ImmunityBioIBRX-042 In Participants With HPV-Associated Tumors Fase 1 12
The goal of this clinical trial is to determine the maximum tolerated dose and to find out the side effects of a drug called IBRX-042 at different dose levels in patients with recurrent or progressive Human Papillomavirus (HPV) associated tumors. The main questions it aims to answer are:
- What is the maximum tolerated dose of IBRX-042?
- How well does the study drug treat cancer?
- What effects the study drug may h...
Participants will receive study treatments until they report progressive disease (PD), unacceptable toxicity, withdraw consent, or if the Investigator feels it is no longer in their best interest to conti...
Toon meerQUILT-3.100: Phase 1 Open-Label Study to Evaluate Safety And Determine The Maximum Tolerated Dose of IBRX-042 In Participants With HPV-Associated Tumors.
- QUILT-3.100
| Deelnemersgroep/Studiearm | Interventie/Behandeling |
|---|---|
ExperimenteelFirst Dose Level Dose Cohort 1: IBRX -042 1e11 virus particles per dose | IBRX-042 * Dose cohort 1: 1e11 virus particles (VP)/dose
* Dose cohort 2: 5e11 VP/dose
* If needed, dose cohort -1 (de-escalation): 5e10 VP/dose |
ExperimenteelSecond Dose Level Dose Cohort 2: IBRX-042 5e11 virus particles per dose | IBRX-042 * Dose cohort 1: 1e11 virus particles (VP)/dose
* Dose cohort 2: 5e11 VP/dose
* If needed, dose cohort -1 (de-escalation): 5e10 VP/dose |
ExperimenteelDe-escalation Dose Level Dose Cohort -1: IBRX-042 5e10 virus particles per dose | IBRX-042 * Dose cohort 1: 1e11 virus particles (VP)/dose
* Dose cohort 2: 5e11 VP/dose
* If needed, dose cohort -1 (de-escalation): 5e10 VP/dose |
| Uitkomstmaat | Beschrijving van de uitkomstmaat | Tijdsbestek |
|---|---|---|
Determine the maximum tolerated dose of IBRX-042 | The rate of DLTs will be assessed and the MTD determined | 1 year |
| Uitkomstmaat | Beschrijving van de uitkomstmaat | Tijdsbestek |
|---|---|---|
Determine the safety profile & reactogenicity of IBRX-042 | Overall safety will be assessed by the incidence of adverse events including: treatment-emergent MAAEs, SAEs, solicited local and systemic reactogenicity AEs, and unsolicited AEs. Adverse Events will be qualified by the time periods of interest, overall and by grade. Adverse events (AEs) will be summarized by System Organ Class (SOC) and Medical Dictionary for Regulatory Activities (MedDRA) preferred term. All AEs will be graded using CTCAE Version 5.0. The incidence of clinically significant changes in safety laboratory tests, physical examinations, ECGs, and vital signs will also be presented. | 2 years |
Examine HPV-specific humoral and cellular immune responses | Summary statistics from analyses of the humoral and cellular immune response endpoints will be provided. Where applicable, geometric mean titers (GMTs) and their associated 95% confidence intervals (CIs) will be computed by exponentiation of the corresponding log-transformed means and 95% CIs. Correlations of humoral and cellular immune response with participants outcomes will be provided. | 2 years |
18-75 years of age.
Able to understand and provide a signed informed consent that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.
Histologically confirmed HPV-associated cancer documented as HPV- or p16-positive carcinoma (measurable or non-measurable disease).
Participants must have received at least 1 standard of care therapy per National Comprehensive Cancer Network (NCCN) guidelines for their HPV-associated cancer > 28 days prior to enrollment.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Resolution of all toxic side effects of prior therapy for their HPV-associated cancer to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5 grade ≤ 1.
Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
Agreement to practice effective contraception for female participants of child-bearing potential and nonsterile males. Female participants of child-bearing potential must agree to use effective contraception for up to 30 days after last dose of study treatment. Nonsterile male participants must agree to use a condom while on study and for up to 30 days after the last dose of study treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, and intrauterine devices (IUDs).
Adequate organ function, evidenced by the following laboratory results:
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Absolute lymphocyte count (ALC) > institutional lower limit of normal
- Hemoglobin ≥ 10.0 g/dL.
- Platelet count ≥ 100 × 109/L
- Total bilirubin ≤ 1.5 × upper limit of normal (ULN; unless the participant has documented Gilbert's syndrome).
- Aspartate aminotransferase \[serum glutamic-oxaloacetic transaminase\] (AST \[SGOT\]) or alanine aminotransferase \[serum glutamic-pyruvic transaminase\] (ALT \[SGPT\]) ≤ 3.0 × ULN. For patients with significant hepatic involvement by tumor, ALT ≤ 5 × ULN is acceptable.
- Albumin ≥ 3.0 g/dL. Note: Each study site should use its institutional ULN to determine eligibility.
- Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drugs used in this study or that would put the participant at high risk for treatment-related complications.
- Serious pulmonary disease.
- Active hepatitis.
- Positive results of screening test for hepatitis B virus and/or hepatitis C virus.
- Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in participants who have known contrast allergies is allowed.
- Participants taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications.
- Participation in an investigational drug study or receiving any investigational treatment within 28 days prior to study treatment. Approved drugs for the prevention and treatment of COVID-19 are permitted.
- Concurrent participation in any interventional clinical trial.
- Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
- Pregnant and nursing women.
ImmunityBioCalifornia
Texas